BUFY01 versus SVS20 eye drops for dry eye disease
Official title: Efficacy and Safety of BUFY01 Versus SVS20 in the Treatment of Dry Eye Disease: a Non-inferiority Investigation
Run by TRB Chemedica International SA · NCT05865379 · Data updated 2026-11-12
We will test whether BUFY01 eye drops work as well as SVS20 eye drops to improve signs and symptoms in adults with dry eye disease.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 80 (estimated) |
| Sponsor | TRB Chemedica International SA Industry-sponsored |
| Locations | 3 sites (Leuven and 2 other locations) |
| Status | Recruiting |
| Started | October 26, 2026 |
| Main results expected | April 2027 |
| Study ends | June 2027 |
| Registry record updated | October 29, 2026 |
| Trial ID | NCT05865379 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults with a documented ≥3‑month history of bilateral dry eye who need artificial tears, have at least one eye with Oxford score 4–9 and at least one objective sign of tear deficiency, who have health insurance and can attend the scheduled visits are ideal candidates.
✕Probably not a fit
People with severe or non‑DED ocular surface disease (for example severe blepharitis, seasonal allergy, recent ocular surgery/injury, unstable glaucoma), recent preservative‑containing artificial tear use, recent contact lens initiation, pregnancy or breastfeeding are unlikely to benefit or be eligible.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Participants are assigned to receive either BUFY01 or SVS20 single‑dose eye drops and will use the allocated treatment every day for three months. They will attend four clinic visits for ocular examinations, complete symptom questionnaires, and return unused study medication. The trial is designed as a head‑to‑head non‑inferiority comparison of effects on objective signs (e.g., ocular surface staining) and patient‑reported symptoms, with monitoring for safety and tolerability. Procedures take place at participating ophthalmology centers in France.
Why it matters
Potential benefit: If successful, this could provide an alternative eye‑drop option with similar effectiveness and safety for people with dry eye disease.
How similar studies have gone: Other non‑inferiority trials and comparable preservative‑free lubricating eye‑drop formulations have demonstrated similar improvements in signs and symptoms, while BUFY01 itself appears to be a newer formulation being directly compared to SVS20.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria includes: * At least a 3-month documented history of bilateral dry eye syndrome needing artificial tears; * At least one eye with Oxford score ≥ 4 and ≤ 9; * At least one objective sign of tear deficiency (in at least one eligible eye); * Having a health insurance. Exclusion Criteria includes: * Wear of contact lenses starting within the last 2 months; * Best-corrected visual acuity (BCVA) \> 1.00; * Severe DED with one of the listed conditions: * Severe blepharitis; * Seasonal allergy; * Any issues of the ocular surface not related to DED; * History of ocular trauma, infection or inflammation not related to DED; * History of ocular surgery, including laser surgery; * Unstable glaucoma; * Use of artificial tears with preservative within the last 2 weeks; * Systemic (enteral or parenteral) or local (topical) use of one of the listed medications: * Known hypersensitivity to any constituent of the study treatments; * Pregnancy or breastfeeding; * Participation in another clinical study within the last 90 days; * Legally restricted autonomy, freedom of decision and action.
Where it's running
-
UZ Leuven
Leuven, Belgium Recruiting -
Hôpital des Quinze-Vingts
Paris, France Recruiting -
CHU Saint-Etienne
Saint-Priest-en-Jarez, France Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
See if TRYPTYR 0.003% helps dry eye symptoms and signs
This study tests whether acoltremon 0.003% can improve symptoms and eye findings in adults with dry eye disease.
-
BL1107 dosing for drying eye redness: finding the lowest effective amount
This trial tests whether different doses of BL1107 can fully reduce conjunctival redness in people with dry eye disease, while keeping participants unaware of the dose they receive.
-
Eye drops from umbilical cord stem cell vesicles to help dry eye
A tiny drop of human umbilical cord stem cell–derived vesicles is applied to the eye daily for four weeks to see if it helps dry eye symptoms and signs.
-
Tear iron levels and dry eye severity
This project will see if the amount of iron in tears is linked to how severe someone's dry eye is by comparing people with dry eye to healthy volunteers.
-
Vitamin A–based eye ointment for dry, burning, or irritated eyes
This trial will try a vitamin A–based ointment called Vit-A-Vision in adults with dry eye symptoms to see if it improves comfort and tear stability.
-
Exploring dry eye disease patterns after cataract surgery
This study looks at how cataract surgery affects dry eye symptoms in patients aged 50 to 90 and tests if using artificial tears helps improve their comfort over time.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.